Carol A Van Hulle
Overview
Explore the profile of Carol A Van Hulle including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
1960
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gooding D, Van Hulle C, Zuelsdorff M, Lewis J, Carter F, Salazar H, et al.
J Alzheimers Dis
. 2025 Jan;
103(3):865-878.
PMID: 39772842
Background: Past research suggests that ethnoracialized groups differ in their willingness to engage in preclinical Alzheimer's disease (AD) research overall. Studies indicated that participation willingness was affected by attitudes toward...
2.
Gooding D, Mohrbacher D, Umucu E, Van Hulle C, Lewis J, Carter F, et al.
Psychiatry Res
. 2024 Feb;
334:115776.
PMID: 38377801
Although there is renewed optimism in biomarker research in schizophrenia, there is also need for greater inclusion of historically underrepresented groups in the research. In the present study, we surveyed...
3.
Hale M, Langhough R, Du L, Hermann B, Van Hulle C, Carboni M, et al.
Neurobiol Aging
. 2023 Nov;
133:87-98.
PMID: 37925995
Neuropsychological measures sensitive to decline in the preclinical phase of Alzheimer's disease are needed. We previously demonstrated that higher amyloid-beta (Aβ) assessed by positron emission tomography in adults without cognitive...
4.
Gallagher R, Langhough Koscik R, Moody J, Vogt N, Adluru N, Kecskemeti S, et al.
Alzheimers Res Ther
. 2023 Oct;
15(1):180.
PMID: 37848950
Background: Alzheimer's disease involves accumulating amyloid (A) and tau (T) pathology, and progressive neurodegeneration (N), leading to the development of the AD clinical syndrome. While several markers of N have...
5.
Dong R, Lu Q, Kang H, Suridjan I, Kollmorgen G, Wild N, et al.
Front Aging Neurosci
. 2023 Sep;
15:1214932.
PMID: 37719875
Introduction: Metabolomics technology facilitates studying associations between small molecules and disease processes. Correlating metabolites in cerebrospinal fluid (CSF) with Alzheimer's disease (AD) CSF biomarkers may elucidate additional changes that are...
6.
Erickson P, Simren J, Brum W, Ennis G, Kollmorgen G, Suridjan I, et al.
JAMA Neurol
. 2023 Jul;
PMID: 37523162
Importance: Knowledge is lacking on the prevalence and prognosis of individuals with a β-amyloid-negative, tau-positive (A-T+) cerebrospinal fluid (CSF) biomarker profile. Objective: To estimate the prevalence of a CSF A-T+...
7.
Xu Y, Vasiljevic E, Deming Y, Jonaitis E, Koscik R, Van Hulle C, et al.
J Alzheimers Dis
. 2023 Jul;
94(4):1587-1605.
PMID: 37482996
Background: Genetic scores for late-onset Alzheimer's disease (LOAD) have been associated with preclinical cognitive decline and biomarker variations. Compared with an overall polygenic risk score (PRS), a pathway-specific PRS (p-PRS)...
8.
Nair A, Van Hulle C, Bendlin B, Zetterberg H, Blennow K, Wild N, et al.
Brain Commun
. 2023 Jun;
5(3):fcad180.
PMID: 37377978
Chronic systemic inflammation increases the risk of neurodegeneration, but the mechanisms remain unclear. Part of the challenge in reaching a nuanced understanding is the presence of multiple risk factors that...
9.
Panyard D, McKetney J, Deming Y, Morrow A, Ennis G, Jonaitis E, et al.
Alzheimers Dement
. 2023 May;
19(12):5447-5470.
PMID: 37218097
Introduction: A hallmark of Alzheimer's disease (AD) is the aggregation of proteins (amyloid beta [A] and hyperphosphorylated tau [T]) in the brain, making cerebrospinal fluid (CSF) proteins of particular interest....
10.
Dong R, Denier-Fields D, Van Hulle C, Kollmorgen G, Suridjan I, Wild N, et al.
Eur J Epidemiol
. 2023 Mar;
38(5):559-571.
PMID: 36964431
Modifiable factors can influence the risk for Alzheimer's disease (AD) and serve as targets for intervention; however, the biological mechanisms linking these factors to AD are unknown. This study aims...